Epilepsy Epidiolex denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for epilepsy epidiolex are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Labels Epidiolex Experimental — and Why That Denial Is Wrong

Epidiolex (cannabidiol) received FDA approval and is not experimental for its approved indications. A denial coded as "experimental" or "investigational" for Epidiolex is almost certainly a coverage-policy mismatch — either the plan's system failed to recognize the FDA-approved indication, the diagnosis code submitted was for a condition the plan has not yet incorporated into its coverage policy, or the policy has not been updated to reflect the current FDA label. This type of denial is among the most overturneable because FDA approval itself refutes the experimental classification.

## Why This Denial Is Appealable

Federal regulations and most state insurance laws hold that FDA-approved drugs used consistent with their approved labeling cannot be classified as experimental or investigational. If Epidiolex is being prescribed for an indication within its FDA-approved label, Cigna's experimental denial is legally and factually unsupported. Even where off-label use is involved, major medical guidelines from organizations such as the American Epilepsy Society and relevant neurological bodies may support coverage under accepted medical practice standards.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 require Cigna to provide a full-and-fair internal review. File within the deadline on your denial letter.
• External review: If Cigna upholds the denial internally, you have approximately four months to escalate to independent external review. An IRO with epilepsy or neurology expertise will apply clinical and regulatory standards — not Cigna's internal policy alone.
• Expedited review: Uncontrolled seizures constitute a serious health risk; request expedited review for a 72-hour decision turnaround.

## Documentation to Gather

1. FDA approval documentation: Print the FDA-approved prescribing information (label) for Epidiolex and highlight the specific indication matching your diagnosis — this is your primary rebuttal to the experimental denial. 2. Diagnosis confirmation: EEG records, genetic panels, clinical notes, and specialist confirmation of the specific epilepsy syndrome. 3. Published guideline support: Ask your neurologist to reference guideline recommendations from the applicable professional organization endorsing Epidiolex's use, without citing specific statistics. 4. Prior ASM history: Documentation of treatments tried before Epidiolex, showing a pattern consistent with treatment-resistant disease. 5. Prescriber medical-necessity letter: A letter from the treating neurologist stating the FDA-approved indication, the patient's confirmed diagnosis, and why the experimental classification is incorrect.

## Criteria-Mapping Structure

Review Cigna's published Epidiolex coverage policy from the Cigna policy portal. For each criterion used to justify the experimental label:

| Cigna Policy Basis for Denial | Rebuttal Evidence | |---|---| | "Lacks sufficient clinical evidence" | [FDA-approved label showing indication] | | "Not consistent with covered benefit" | [Diagnosis match to FDA-labeled indication] | | "Investigational for this diagnosis" | [Neurologist letter + guideline reference] |

A cover letter citing the FDA approval date and approved indication, attached to the prescribing information, is often enough to resolve this denial at the internal appeal stage.